CAR T-cell Therapy Market (Product Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel, and Others; Indication: Acute Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell

CAR T-cell Therapy Market (Product Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel, and Others; Indication: Acute Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, and Others; and End-user: Hospitals and Cancer Treatment Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

CAR T-cell Therapy Market – Scope of Report

TMR’s report on the global CAR T-cell therapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global CAR T-cell therapy market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global CAR T-cell therapy market from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the CAR T-cell therapy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global CAR T-cell therapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global CAR T-cell therapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global CAR T-cell therapy market.

The report delves into the competitive landscape of the global CAR T-cell therapy market. Key players operating in the global CAR T-cell therapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global CAR T-cell therapy market profiled in this report.

Key Questions Answered in CAR T-cell Therapy Market Report

What is the sales/revenue generated by CAR T-cell therapy across all regions during the forecast period?
What are the opportunities in the global CAR T-cell therapy market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which product type is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
What is the market position of different companies operating in the global market?
CAR T-cell Therapy Market – Research Objectives and Research Approach

The comprehensive report on the global CAR T-cell therapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global CAR T-cell therapy market in terms of product type, indication, end-user, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global CAR T-cell therapy market.


1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global CAR T-cell Therapy Market Forecast
4.4. Global CAR T-cell Therapy Market Outlook
5. Market Outlook
5.1. Key Industry Events
5.2. Diseases Epidemiology
5.3. Product Pipeline Analysis
5.4. Impact of COVID-19 Pandemic
6. Global CAR T-cell Therapy Market Analysis, by Product Type
6.1. Introduction
6.2. Global CAR T-cell Therapy Market Value Share Analysis, by Product Type
6.3. Global CAR T-cell Therapy Market Forecast, by Product Type
6.3.1. Axicabtagene Ciloleucel
6.3.2. Tisagenlecleucel
6.3.3. Brexucabtagene Autoleucel
6.3.4. Lisocabtagene Maraleucel
6.3.5. Idecabtagene Vicleucel
6.3.6. Others
6.4. Global CAR T-cell Therapy Market Analysis, by Product Type
6.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Product Type
7. Global CAR T-cell Therapy Market Analysis, by Indications
7.1. Introduction
7.2. Global CAR T-cell Therapy Market Value Share Analysis, by Indication
7.3. Global CAR T-cell Therapy Market Forecast, by Indication
7.3.1. Acute Lymphocytic Leukemia
7.3.2. Diffuse Large B-Cell Lymphoma
7.3.3. Follicular Lymphoma
7.3.4. Mantle Cell Lymphoma
7.3.5. Multiple Myeloma
7.3.6. Others
7.4. Global CAR T-cell Therapy Market Analysis, by Indication
7.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Indication
8. Global CAR T-cell Therapy Market Analysis, by End-user
8.1. Introduction
8.2. Global CAR T-cell Therapy Market Value Share Analysis, by End-user
8.3. Global CAR T-cell Therapy Market Forecast, by End-user
8.3.1. Hospitals
8.3.2. Cancer Treatment Centers
8.4. Global CAR T-cell Therapy Market Analysis, by End-user
8.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by End-user
9. Global CAR T-cell Therapy Market Analysis, by Region
9.1. Global CAR T-cell Therapy Market Analysis, by Region
9.2. Global CAR T-cell Therapy Market Value Share Analysis, by Region
9.3. Global CAR T-cell Therapy Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America CAR T-cell Therapy Market Analysis
10.1. North America CAR T-cell Therapy Market Overview
10.2. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country
10.3. North America CAR T-cell Therapy Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
10.5. North America CAR T-cell Therapy Market Forecast, by Product Type
10.5.1. Axicabtagene Ciloleucel
10.5.2. Tisagenlecleucel
10.5.3. Brexucabtagene Autoleucel
10.5.4. Lisocabtagene Maraleucel
10.5.5. Idecabtagene Vicleucel
10.5.6. Others
10.6. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indications
10.7. North America CAR T-cell Therapy Market Forecast, by Indication
10.7.1. Acute Lymphocytic Leukemia
10.7.2. Diffuse Large B-Cell Lymphoma
10.7.3. Follicular Lymphoma
10.7.4. Mantle Cell Lymphoma
10.7.5. Multiple Myeloma
10.7.6. Others
10.8. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
10.9. North America CAR T-cell Therapy Market Forecast, by End-user
10.9.1. Hospitals
10.9.2. Cancer Treatment Centers
11. Europe CAR T-cell Therapy Market Analysis
11.1. Europe CAR T-cell Therapy Market Overview
11.2. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe CAR T-cell Therapy Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
11.5. Europe CAR T-cell Therapy Market Forecast, by Product Type
11.5.1. Axicabtagene Ciloleucel
11.5.2. Tisagenlecleucel
11.5.3. Brexucabtagene Autoleucel
11.5.4. Lisocabtagene Maraleucel
11.5.5. Idecabtagene Vicleucel
11.5.6. Others
11.6. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
11.7. Europe CAR T-cell Therapy Market Forecast, by Indication
11.7.1. Acute Lymphocytic Leukemia
11.7.2. Diffuse Large B-Cell Lymphoma
11.7.3. Follicular Lymphoma
11.7.4. Mantle Cell Lymphoma
11.7.5. Multiple Myeloma
11.7.6. Others
11.8. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
11.9. Europe CAR T-cell Therapy Market Forecast, by End-user
11.9.1. Hospitals
11.9.2. Cancer Treatment Centers
12. Asia Pacific CAR T-cell Therapy Market Analysis
12.1. Asia Pacific CAR T-cell Therapy Market Overview
12.2. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific CAR T-cell Therapy Market Forecast, by Country/Sub-region
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
12.5. Asia Pacific CAR T-cell Therapy Market Forecast, by Product Type
12.5.1. Axicabtagene Ciloleucel
12.5.2. Tisagenlecleucel
12.5.3. Brexucabtagene Autoleucel
12.5.4. Lisocabtagene Maraleucel
12.5.5. Idecabtagene Vicleucel
12.5.6. Others
12.6. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
12.7. Asia Pacific CAR T-cell Therapy Market Forecast, by Indication
12.7.1. Acute Lymphocytic Leukemia
12.7.2. Diffuse Large B-Cell Lymphoma
12.7.3. Follicular Lymphoma
12.7.4. Mantle Cell Lymphoma
12.7.5. Multiple Myeloma
12.7.6. Others
12.8. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
12.9. Asia Pacific CAR T-cell Therapy Market Forecast, by End-user
12.9.1. Hospitals
12.9.2. Cancer Treatment Centers
13. Latin America CAR T-cell Therapy Market Analysis
13.1. Latin America CAR T-cell Therapy Market Overview
13.2. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America CAR T-cell Therapy Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
13.5. Latin America CAR T-cell Therapy Market Forecast, by Product Type
13.5.1. Axicabtagene Ciloleucel
13.5.2. Tisagenlecleucel
13.5.3. Brexucabtagene Autoleucel
13.5.4. Lisocabtagene Maraleucel
13.5.5. Idecabtagene Vicleucel
13.5.6. Others
13.6. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
13.7. Latin America CAR T-cell Therapy Market Forecast, by Indication
13.7.1. Acute Lymphocytic Leukemia
13.7.2. Diffuse Large B-Cell Lymphoma
13.7.3. Follicular Lymphoma
13.7.4. Mantle Cell Lymphoma
13.7.5. Multiple Myeloma
13.7.6. Others
13.8. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
13.9. Latin America CAR T-cell Therapy Market Forecast, by End-user
13.9.1. Hospitals
13.9.2. Cancer Treatment Centers
14. Middle East & Africa CAR T-cell Therapy Market Analysis
14.1. Middle East & Africa CAR T-cell Therapy Market Overview
14.2. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa CAR T-cell Therapy Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
14.5. Middle East & Africa CAR T-cell Therapy Market Forecast, by Product Type
14.5.1. Axicabtagene Ciloleucel
14.5.2. Tisagenlecleucel
14.5.3. Brexucabtagene Autoleucel
14.5.4. Lisocabtagene Maraleucel
14.5.5. Idecabtagene Vicleucel
14.5.6. Others
14.6. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
14.7. Middle East & Africa CAR T-cell Therapy Market Forecast, by Indication
14.7.1. Acute Lymphocytic Leukemia
14.7.2. Diffuse Large B-Cell Lymphoma
14.7.3. Follicular Lymphoma
14.7.4. Mantle Cell Lymphoma
14.7.5. Multiple Myeloma
14.7.6. Others
14.8. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
14.9. Middle East & Africa CAR T-cell Therapy Market Forecast, by End-user
14.9.1. Hospitals
14.9.2. Cancer Treatment Centers
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. Pfizer Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Bristol-Myers Squibb
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Amgen, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Sorrento Therapeutics, Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Johnson & Johnson Services, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Gilead Sciences, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Merck & Co., Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. bluebird bio, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings